Guggenheim initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $5 price target The firm’s investment thesis on the stock i...
Guggenheim initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $5 price target The firm’s investment thesis on the stock i...